Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

ESMO 2019

27 Sep - 1 Oct 2019
Fira Barcelona, Barcelona, Spain
PROfound: PARP inhibitor olaparib compared with new hormonal agents in advanced ...
Prof Maha Hussain - Northwestern University Feinberg School of Medicine, Chicago...
PROfound: PARP inhibitor olaparib compared with new hormonal agents in advanced castration resistant prostate cancer ( Prof Maha Hussain - Northwestern University Feinberg School of Medicine, Chicago, USA )
7 Nov 2019
Analysis of assay used in IMpassion130 to guide treatment of metastatic and adva...
Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia
Analysis of assay used in IMpassion130 to guide treatment of metastatic and advanced breast cancers ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )
31 Oct 2019
GORTEC: Cisplatin chemoradiation plus debio 1143 in patients with locally advanc...
Prof Jean Bourhis - Lausanne University Hospital, Lausanne, Switzerland
GORTEC: Cisplatin chemoradiation plus debio 1143 in patients with locally advanced head and neck squamous cell carcinoma ( Prof Jean Bourhis - Lausanne University Hospital, Lausanne, Switzerland )
14 Oct 2019
Simplifying molecular subtypes of metastatic gastric cancer
Dr Maria Alsina - Vall d'Hebron Instituto de Oncología (VHIO), Barcelona, Spain
Simplifying molecular subtypes of metastatic gastric cancer ( Dr Maria Alsina - Vall d'Hebron Instituto de Oncología (VHIO), Barcelona, Spain )
8 Oct 2019
Quality of life results from pembrolizumab vs chemotherapy in gastric or gastroe...
Dr Maria Alsina - Vall d'Hebron Instituto de Oncología (VHIO), Barcelona, Spain
Quality of life results from pembrolizumab vs chemotherapy in gastric or gastroesophageal junction cancer ( Dr Maria Alsina - Vall d'Hebron Instituto de Oncología (VHIO), Barcelona, Spain )
8 Oct 2019
TROPHY-U-01: Sacituzumab govitecan in patients with mUC after failure of platinu...
Dr Scott Tagawa - Weill Cornell Medicine, New York City, USA
TROPHY-U-01: Sacituzumab govitecan in patients with mUC after failure of platinum-based regimens or immunotherapy ( Dr Scott Tagawa - Weill Cornell Medicine, New York City, USA )
7 Oct 2019
VOLFI: FOLFOXIRI and panitumumab in RAS wild-type metastatic colorectal cancer
Dr Dominik Modest - Charité Universitätsmedizin Berlin, Berlin, Germany
VOLFI: FOLFOXIRI and panitumumab in RAS wild-type metastatic colorectal cancer ( Dr Dominik Modest - Charité Universitätsmedizin Berlin, Berlin, Germany )
7 Oct 2019
CARD: Cabazitaxel vs abiraterone or enzalutamide in metastatic castration-resist...
Prof Ronald de Wit - Erasmus University Medical Center, Rotterdam, Netherlands
CARD: Cabazitaxel vs abiraterone or enzalutamide in metastatic castration-resistant prostate cancer ( Prof Ronald de Wit - Erasmus University Medical Center, Rotterdam, Netherlands )
7 Oct 2019
Niraparib therapy in patients with newly diagnosed advanced ovarian cancer
Dr Antonio González-Martín - Clínica Universidad de Navarra, Madrid, Spain
Niraparib therapy in patients with newly diagnosed advanced ovarian cancer ( Dr Antonio González-Martín - Clínica Universidad de Navarra, Madrid, Spain )
7 Oct 2019
IMspire170: New combination treatment for advanced melanoma
Dr Ana Arance - Hospital Clinic Barcelona, Barcelona, Spain
IMspire170: New combination treatment for advanced melanoma ( Dr Ana Arance - Hospital Clinic Barcelona, Barcelona, Spain )
7 Oct 2019
CheckMate 067: Nivolumab plus ipilimumab combination therapy in advanced melanom...
Dr Ana Arance - Hospital Clinic Barcelona, Barcelona, Spain
CheckMate 067: Nivolumab plus ipilimumab combination therapy in advanced melanoma ( Dr Ana Arance - Hospital Clinic Barcelona, Barcelona, Spain )
7 Oct 2019
ARIEL3: Rucaparib maintenance treatment for recurrent ovarian carcinoma
Dr Jonathan Ledermann - University College Hospital, London, UK
ARIEL3: Rucaparib maintenance treatment for recurrent ovarian carcinoma ( Dr Jonathan Ledermann - University College Hospital, London, UK )
7 Oct 2019
PROMISE-meso trial results: Pembrolizumab vs chemotherapy for advanced pleural m...
Prof Sanjay Popat - The Royal Marsden Hospital, London, UK
PROMISE-meso trial results: Pembrolizumab vs chemotherapy for advanced pleural mesothelioma ( Prof Sanjay Popat - The Royal Marsden Hospital, London, UK )
7 Oct 2019
Checkmate 227: Final analysis for the non small cell lung cancer trial
Prof Sanjay Popat - The Royal Marsden Hospital, London, UK
Checkmate 227: Final analysis for the non small cell lung cancer trial ( Prof Sanjay Popat - The Royal Marsden Hospital, London, UK )
7 Oct 2019
PARP inhibitors for metastatic breast cancer
Prof Michael Untch - Helios Hospital Berlin-Buch, Berlin, Germany
PARP inhibitors for metastatic breast cancer ( Prof Michael Untch - Helios Hospital Berlin-Buch, Berlin, Germany )
7 Oct 2019
KATHERINE trial updates for HER2-positive breast cancer
Prof Michael Untch - Helios Hospital Berlin-Buch, Berlin, Germany
KATHERINE trial updates for HER2-positive breast cancer ( Prof Michael Untch - Helios Hospital Berlin-Buch, Berlin, Germany )
7 Oct 2019
TRITON2: Rucaparib for metastatic castration-resistant prostate cancer
Prof Ray McDermott - St. Vincents University Hospital, Dublin, Republic of Irela...
TRITON2: Rucaparib for metastatic castration-resistant prostate cancer ( Prof Ray McDermott - St. Vincents University Hospital, Dublin, Republic of Ireland )
7 Oct 2019
Lutetium-177 PSMA scanning for prostate cancer
Dr Scott Tagawa - Weill Cornell Medicine, New York City, USA
Lutetium-177 PSMA scanning for prostate cancer ( Dr Scott Tagawa - Weill Cornell Medicine, New York City, USA )
7 Oct 2019
Highlights from ESMO 2019
Prof Josep Tabernero - ESMO President
Highlights from ESMO 2019 ( Prof Josep Tabernero - ESMO President )
4 Oct 2019
SPICE: Analysis of enadenotucirev plus nivolumab in metastatic colorectal cancer...
Prof Marwan Fakih - City of Hope National Medical Center, Duarte, USA
SPICE: Analysis of enadenotucirev plus nivolumab in metastatic colorectal cancer patients during the dose escalation phase ( Prof Marwan Fakih - City of Hope National Medical Center, Duarte, USA )
4 Oct 2019
Nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC
Prof Ahmed Kaseb - MD Anderson Cancer Center, Houston, USA
Nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC ( Prof Ahmed Kaseb - MD Anderson Cancer Center, Houston, USA )
4 Oct 2019
Pembrolizumab plus platinum-based chemotherapy for metastatic NSCLC
Dr Luis Paz-Ares - Hospital Universitario Doce de Octubre, Madrid, Spain
Pembrolizumab plus platinum-based chemotherapy for metastatic NSCLC ( Dr Luis Paz-Ares - Hospital Universitario Doce de Octubre, Madrid, Spain )
4 Oct 2019
Association between tTMB and clinical outcomes with pembrolizumab alone in PD-L1...
Prof Roy Herbst - Yale Cancer Center, New Haven, USA
Association between tTMB and clinical outcomes with pembrolizumab alone in PD-L1-positive advanced NSCLC in KEYNOTE-010 and -042 ( Prof Roy Herbst - Yale Cancer Center, New Haven, USA )
4 Oct 2019
IMPALA results: Lefitolimod vs standard of care in metastatic colorectal cancer
Dr Ramon Salazar - Catalan Institute of Oncology, Barcelona, Spain
IMPALA results: Lefitolimod vs standard of care in metastatic colorectal cancer ( Dr Ramon Salazar - Catalan Institute of Oncology, Barcelona, Spain )
4 Oct 2019
AMG 510: A novel molecule targeting KRAS G12C mutant solid tumours
Prof Marwan Fakih - City of Hope National Medical Center, Duarte, USA
AMG 510: A novel molecule targeting KRAS G12C mutant solid tumours ( Prof Marwan Fakih - City of Hope National Medical Center, Duarte, USA )
4 Oct 2019
MEDIOLA: Olaparib and durvalumab for germline BRCA-mutated metastatic breast can...
Prof Susan Domchek - University of Pennsylvania, Pennsylvania, USA
MEDIOLA: Olaparib and durvalumab for germline BRCA-mutated metastatic breast cancer ( Prof Susan Domchek - University of Pennsylvania, Pennsylvania, USA )
4 Oct 2019
Blood first assay screening in patients with ALK positive NSCLC
Prof Shirish Gadgeel - University of Michigan, Ann Arbor, USA
Blood first assay screening in patients with ALK positive NSCLC ( Prof Shirish Gadgeel - University of Michigan, Ann Arbor, USA )
4 Oct 2019
Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative ad...
Dr Véronique Diéras - Centre Eugène Marquis, Rennes, France
Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer ( Dr Véronique Diéras - Centre Eugène Marquis, Rennes, France )
4 Oct 2019
CUPISCO: Identifying carcinoma of unknown primary patients according to ESMO gui...
Prof Jeffrey S. Ross - Albany Medical Center, Albany, USA
CUPISCO: Identifying carcinoma of unknown primary patients according to ESMO guidelines ( Prof Jeffrey S. Ross - Albany Medical Center, Albany, USA )
4 Oct 2019
CheckMate 459: Safety and efficacy of nivolumab versus sorafenib as a first-line...
Dr Thomas Yau - The University of Hong Kong, Hong Kong
CheckMate 459: Safety and efficacy of nivolumab versus sorafenib as a first-line treatment in advanced hepatocellular carcinoma ( Dr Thomas Yau - The University of Hong Kong, Hong Kong )
4 Oct 2019
Optimal timing of radiotherapy following radical prostatectomy
Prof Chris Parker - The Royal Marsden Hospital, London, UK
Optimal timing of radiotherapy following radical prostatectomy ( Prof Chris Parker - The Royal Marsden Hospital, London, UK )
4 Oct 2019
Safety and tolerability of AVB500 in platinum-resistant recurrent ovarian cancer
Dr Gail McIntyre - CSO, Aravive Biologics, Houston, Texas
Safety and tolerability of AVB500 in platinum-resistant recurrent ovarian cancer ( Dr Gail McIntyre - CSO, Aravive Biologics, Houston, Texas )
4 Oct 2019
INVICTUS: Assessing the safety and efficacy of ripretinib in patients with advan...
Prof Margaret von Mehren - Fox Chase Cancer Center, Philadelphia, USA
INVICTUS: Assessing the safety and efficacy of ripretinib in patients with advanced gastrointestinal stromal tumours ( Prof Margaret von Mehren - Fox Chase Cancer Center, Philadelphia, USA )
3 Oct 2019
Using PARP inhibitors to improve quality of life for patients with metastatic br...
Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia
Using PARP inhibitors to improve quality of life for patients with metastatic breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )
3 Oct 2019
Holistic management of patients with ALK-positive NSCLC
Rachel Thomas and Jackie Fenemore
Holistic management of patients with ALK-positive NSCLC ( Rachel Thomas and Jackie Fenemore )
3 Oct 2019
Precision medicine in ALK-positive NSCLC: Results from the BFAST trial
Prof Solange Peters and Prof Tony Mok
Precision medicine in ALK-positive NSCLC: Results from the BFAST trial ( Prof Solange Peters and Prof Tony Mok )
3 Oct 2019
Prostate cancer updates: Advances in precision medicine and PARP inhibitors
Prof Karim Fizazi, Dr Joaquin Mateo, Dr Shahneen Sandhu and Prof Bertrand Tombal
Prostate cancer updates: Advances in precision medicine and PARP inhibitors ( Prof Karim Fizazi, Dr Joaquin Mateo, Dr Shahneen Sandhu and Prof Bertrand Tombal )
2 Oct 2019
Health-related quality of life for patients with metastatic pancreatic cancer: U...
Prof Eric Van Cutsem and Dr Teresa Macarulla
Health-related quality of life for patients with metastatic pancreatic cancer: Updates from ESMO 2019 ( Prof Eric Van Cutsem and Dr Teresa Macarulla )
2 Oct 2019
Role of molecular diagnostics in prostate cancer
Dr Elena Castro and Dr Shahneen Sandhu
Role of molecular diagnostics in prostate cancer ( Dr Elena Castro and Dr Shahneen Sandhu )
2 Oct 2019
Key developments in pancreatic cancer from ESMO 2019
Prof Eileen O'Reilly and Dr Ian Chau
Key developments in pancreatic cancer from ESMO 2019 ( Prof Eileen O'Reilly and Dr Ian Chau )
2 Oct 2019
Breast cancer highlights from ESMO 2019
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
Breast cancer highlights from ESMO 2019 ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )
2 Oct 2019
Melanoma highlights from ESMO 2019
Dr Teresa Amaral - University Hospital Tübingen, Tübingen, Germany
Melanoma highlights from ESMO 2019 ( Dr Teresa Amaral - University Hospital Tübingen, Tübingen, Germany )
30 Sep 2019
ClarIDHy: Targeted therapy ivosidenib for advanced cholangiocarcinoma
Prof Ghassan Abou-Alfa - Memorial Sloan Kettering Cancer Center, New York City, ...
ClarIDHy: Targeted therapy ivosidenib for advanced cholangiocarcinoma ( Prof Ghassan Abou-Alfa - Memorial Sloan Kettering Cancer Center, New York City, USA )
30 Sep 2019
IMvigor130: Immunotherapy added to chemotherapy in metastatic urothelial cancer
Dr Enrique Grande - Hospital MD Anderson Cancer Center Madrid, Madrid, Spain
IMvigor130: Immunotherapy added to chemotherapy in metastatic urothelial cancer ( Dr Enrique Grande - Hospital MD Anderson Cancer Center Madrid, Madrid, Spain )
30 Sep 2019
Bladder cancer: Latest advances in targeted therapies and precision medicine fro...
Dr Javier Puente, Prof Maria De Santis, Dr Yohann Loriot, Dr Eva Comperat and Dr...
Bladder cancer: Latest advances in targeted therapies and precision medicine from ESMO 2019 ( Dr Javier Puente, Prof Maria De Santis, Dr Yohann Loriot, Dr Eva Comperat and Dr Michiel Van der Heijden )
30 Sep 2019
Latest developments in metastatic prostate cancer from ESMO 2019
Prof Nick James and Prof Nicholas Mottet
Latest developments in metastatic prostate cancer from ESMO 2019 ( Prof Nick James and Prof Nicholas Mottet )
30 Sep 2019
PARP inhibitor olaparib slows progression of advanced prostate cancer
Prof Maha Hussain - Northwestern University Feinberg School of Medicine, Chicago...
PARP inhibitor olaparib slows progression of advanced prostate cancer ( Prof Maha Hussain - Northwestern University Feinberg School of Medicine, Chicago, USA )
30 Sep 2019
Role of biomarkers, targeted therapy and tumour mutations in the landscape of bl...
Prof Petros Grivas and Dr Michiel Van der Heijden
Role of biomarkers, targeted therapy and tumour mutations in the landscape of bladder cancer ( Prof Petros Grivas and Dr Michiel Van der Heijden )
30 Sep 2019
Comment: PARP inhibitors for advanced prostate cancer
Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain
Comment: PARP inhibitors for advanced prostate cancer ( Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain )
30 Sep 2019
Comment: Immunotherapy plus chemotherapy in bladder cancer
Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain
Comment: Immunotherapy plus chemotherapy in bladder cancer ( Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain )
30 Sep 2019
Targeted therapy ivosidenib shows clinical benefit in cholangiocarcinoma
Prof Ghassan Abou-Alfa - Memorial Sloan Kettering Cancer Center, New York City, ...
Targeted therapy ivosidenib shows clinical benefit in cholangiocarcinoma ( Prof Ghassan Abou-Alfa - Memorial Sloan Kettering Cancer Center, New York City, USA )
30 Sep 2019
Atezolizumab added to chemotherapy prolongs progression free survival in bladder...
Dr Enrique Grande - Hospital MD Anderson Cancer Center Madrid, Madrid, Spain
Atezolizumab added to chemotherapy prolongs progression free survival in bladder cancer ( Dr Enrique Grande - Hospital MD Anderson Cancer Center Madrid, Madrid, Spain )
30 Sep 2019
Comment: Targeted therapy ivosidenib in cholangiocarcinoma
Dr Angela Lamarca - The Christie NHS Foundation Trust, Manchester, UK
Comment: Targeted therapy ivosidenib in cholangiocarcinoma ( Dr Angela Lamarca - The Christie NHS Foundation Trust, Manchester, UK )
30 Sep 2019
Targeted therapies in prostate cancer: Recent advances presented at ESMO 2019
Dr Eleni Efstathiou, Prof Noel Clarke, Dr Elena Castro, Prof Matthew Smith
Targeted therapies in prostate cancer: Recent advances presented at ESMO 2019 ( Dr Eleni Efstathiou, Prof Noel Clarke, Dr Elena Castro, Prof Matthew Smith )
30 Sep 2019
BEACON: Encorafenib plus cetuximab with or without binimetinib for BRAF V600E–mu...
Prof Josep Tabernero - Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Sp...
BEACON: Encorafenib plus cetuximab with or without binimetinib for BRAF V600E–mutant metastatic colorectal cancer ( Prof Josep Tabernero - Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain )
30 Sep 2019
Comment: Pembro plus chemo in neoadjuvant and adjuvant treatment for early tripl...
Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia
Comment: Pembro plus chemo in neoadjuvant and adjuvant treatment for early triple-negative breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )
29 Sep 2019
Comment: Veliparib with carboplatin and paclitaxel in advanced gBRCA-positive br...
Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia
Comment: Veliparib with carboplatin and paclitaxel in advanced gBRCA-positive breast cancers ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )
29 Sep 2019
KEYNOTE-522: Immunotherapy and chemo for early triple negative breast cancer
Prof Peter Schmid - St Bartholomew's Hospital London, London, UK
KEYNOTE-522: Immunotherapy and chemo for early triple negative breast cancer ( Prof Peter Schmid - St Bartholomew's Hospital London, London, UK )
29 Sep 2019
MONALEESA-3: Ribociclib plus fulvestrant in advanced breast cancer
Prof Dennis Slamon - Ronald Reagan UCLA Medical Center, Los Angeles, USA
MONALEESA-3: Ribociclib plus fulvestrant in advanced breast cancer ( Prof Dennis Slamon - Ronald Reagan UCLA Medical Center, Los Angeles, USA )
29 Sep 2019
Improvement in OS with abemaciclib plus fulvestrant in pre-, peri- and postmenop...
Prof George Sledge - Stanford Health Care, Stanford, USA
Improvement in OS with abemaciclib plus fulvestrant in pre-, peri- and postmenopausal HR-positive, HER2-negative advanced breast cancer resistant to hormonal therapy ( Prof George Sledge - Stanford Health Care, Stanford, USA )
29 Sep 2019
Comment: Keynote 522 trial
Prof Guiseppe Curigliano - European Institute of Oncology, Milan, Italy
Comment: Keynote 522 trial ( Prof Guiseppe Curigliano - European Institute of Oncology, Milan, Italy )
29 Sep 2019
CDK4/6 inhibitor ribociclib plus fulvestrant improves overall survival in postme...
Prof Dennis Slamon - Ronald Reagan UCLA Medical Center, Los Angeles, California
CDK4/6 inhibitor ribociclib plus fulvestrant improves overall survival in postmenopausal HR-positive HER2-negative breast cancer ( Prof Dennis Slamon - Ronald Reagan UCLA Medical Center, Los Angeles, California )
29 Sep 2019
CDK4/6 inhibitor abemaciclib plus fulvestrant improves overall survival in HR-po...
Prof George Sledge - Stanford Health Care, Stanford, USA
CDK4/6 inhibitor abemaciclib plus fulvestrant improves overall survival in HR-positive/HER2-negative advanced breast cancer ( Prof George Sledge - Stanford Health Care, Stanford, USA )
29 Sep 2019
Comment: CDK4/6 inhibitors in advanced breast cancer
Prof Nadia Harbeck - University of Munich, Munich, Germany
Comment: CDK4/6 inhibitors in advanced breast cancer ( Prof Nadia Harbeck - University of Munich, Munich, Germany )
29 Sep 2019
Immunotherapy added to chemotherapy improves pathological complete response in e...
Prof Peter Schmid - St Bartholomew's Hospital London, London, UK
Immunotherapy added to chemotherapy improves pathological complete response in early triple negative breast cancer ( Prof Peter Schmid - St Bartholomew's Hospital London, London, UK )
29 Sep 2019
ATTRACTION-3: Nivolumab versus chemotherapy in advanced oesophageal squamous cel...
Prof Byoung Chul Cho - Yonsei University, Seoul, South Korea
ATTRACTION-3: Nivolumab versus chemotherapy in advanced oesophageal squamous cell carcinoma ( Prof Byoung Chul Cho - Yonsei University, Seoul, South Korea )
29 Sep 2019
Ovarian highlights from ESMO 2019
Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA
Ovarian highlights from ESMO 2019 ( Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA )
28 Sep 2019
VELIA/GOG-3005 trial: Veliparib for high-grade serous carcinoma of ovarian, fall...
Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA
VELIA/GOG-3005 trial: Veliparib for high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin ( Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA )
28 Sep 2019
Comment: Nivolumab plus ipilimumab combination for advanced NSCLC
Dr Marina Garassino - National Tumor Institute, Milan, Italy
Comment: Nivolumab plus ipilimumab combination for advanced NSCLC ( Dr Marina Garassino - National Tumor Institute, Milan, Italy )
28 Sep 2019
PARP inhibitor olaparib added to bevacizumab benefits women with ovarian cancer ...
Prof Isabelle Ray-Coquard - The Université Claude Bernard Lyon, Lyon, France
PARP inhibitor olaparib added to bevacizumab benefits women with ovarian cancer with and without a BRCA mutation ( Prof Isabelle Ray-Coquard - The Université Claude Bernard Lyon, Lyon, France )
28 Sep 2019
Comment: Osimertinib for EGFR-mutation positive NSCLC
Dr Pilar Garrido - University Hospital Ramón y Cajal, Madrid, Spain
Comment: Osimertinib for EGFR-mutation positive NSCLC ( Dr Pilar Garrido - University Hospital Ramón y Cajal, Madrid, Spain )
28 Sep 2019
Nivolumab plus ipilimumab combination offers chemotherapy-free option for advanc...
Prof Solange Peters - Centre Hospitalier Universitaire Vaudois, Lausanne, Switze...
Nivolumab plus ipilimumab combination offers chemotherapy-free option for advanced NSCLC ( Prof Solange Peters - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland )
28 Sep 2019
Front-line osimertinib significantly lengthens overall survival in EGFR-mutation...
Prof Suresh Ramalingam - Winship Cancer Institute of Emory University, Atlanta, ...
Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positive NSCLC ( Prof Suresh Ramalingam - Winship Cancer Institute of Emory University, Atlanta, USA )
28 Sep 2019
Comment: PARP inhibitor olaparib plus bevacizumab in women with ovarian cancer
Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK
Comment: PARP inhibitor olaparib plus bevacizumab in women with ovarian cancer ( Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK )
28 Sep 2019
More ovarian cancer patients benefit from maintenance combined targeted therapy
Prof Isabelle Ray-Coquard - The Université Claude Bernard Lyon, Lyon, France
More ovarian cancer patients benefit from maintenance combined targeted therapy ( Prof Isabelle Ray-Coquard - The Université Claude Bernard Lyon, Lyon, France )
28 Sep 2019
Comment: Immunotherapy combination for advanced NSCLC
Dr Marina Garassino - National Tumour Institute, Milan, Italy
Comment: Immunotherapy combination for advanced NSCLC ( Dr Marina Garassino - National Tumour Institute, Milan, Italy )
28 Sep 2019
Comment: Front-line osimertinib significantly lengthens overall survival in EGFR...
Dr Marina Garassino - National Tumour Institute, Milan, Italy
Comment: Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positive NSCLC ( Dr Marina Garassino - National Tumour Institute, Milan, Italy )
28 Sep 2019